logo
Share SHARE
FONT-SIZE Plus   Neg

Medtronic Posts Results From Trial Evaluating Its CoreValve System

Medtronic, Inc. (MDT) announced results from its largest international, prospective, single-arm clinical trial evaluating the Medtronic CoreValve System in patients with severe aortic stenosis who are at high-risk for surgical aortic valve replacement, or SAVR.

The data showed that patients in a real-world setting experienced high procedural success combined with positive clinical outcomes. At present, the CoreValve System is limited to investigational use in the United States.

Called the Medtronic CoreValve ADVANCE Study, survival rates were high at both 30 days and 6 months, rates that are consistent with previously reported data from national registries in Europe. The procedural success rate was 97.8 percent, and overall complication rates were low with stroke rates of 2.9 percent and MACCE (Major Adverse Cardiac & Cerebrovascular Events) rates of 8.3 percent at 30 days. Also, patients in the study experienced significant improvement in valve function.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Even after two years of thoroughly searching across the Indian Ocean, using modern technologies and devices, there is no clue about the Malaysian airline that vanished on March 8, 2014. Internet access is growing worldwide, but there is still a long way to go before the entire world is completely wired, a study from the Pew Research Center has found. The study also noted that men have greater access to the Internet than women in many nations. Backtracking on its early announcements on digital privacy, WhatsApp is planning to share member information, phone numbers and analytical data with Facebook, to make revenue from the platform.
comments powered by Disqus
Follow RTT